UB Therapeutics

Therapy for the Treatment of Multiple Myeloma

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in January 2023 by Ashraf Brik, UB Therapeutics operates with 1–10 employees. The company has raised $415.42K across one funding round from two investors. In February 2023, the company secured pre-seed funding from NGT HealthCare II and Israel Innovation Authority.

Business overview

UB Therapeutics is a biotechnology company focused on developing a novel therapy for the treatment of multiple myeloma. The company's core technology involves a cyclic peptide compound designed to block the action of deubiquitinases and the proteasome, inducing apoptosis in vitro and attenuating tumor growth in vivo. These cyclic peptides demonstrate activity comparable to small molecule proteasome inhibitors, targeting the recognition and proteasomal degradation of ubiquitinylated proteins. UB Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare and life sciences markets.

Strategic signal

In August 2023, UB Therapeutics was highlighted for its work in combating cancer drug resistance. This signals the company's potential to address a critical challenge in oncology, indicating a strategic focus on developing innovative solutions for difficult-to-treat cancers and validating its research direction for investors and innovation teams.

Company Intelligence Q&A

What is UB Therapeutics' primary focus?
UB Therapeutics is a biotechnology company dedicated to developing a novel therapy for the treatment of multiple myeloma.
When was UB Therapeutics founded?
UB Therapeutics was founded in January 2023.
What is the company's core technology?
The company's core technology involves a cyclic peptide compound designed to block deubiquitinases and the proteasome, inducing apoptosis and attenuating tumor growth.
Which investors participated in UB Therapeutics' pre-seed funding round?
In February 2023, UB Therapeutics secured pre-seed funding from NGT HealthCare II and Israel Innovation Authority.
What significant recognition did UB Therapeutics receive in August 2023?
In August 2023, UB Therapeutics was recognized for its efforts in fighting against cancer drug resistance.

External links